Abcam, ab251250, Anti-FCRL2 antibody [EPR16122] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal FCRL2 antibody. Carrier free. Suitable for IP, WB and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR16122,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:IP, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab251250 is the carrier-free version of
ab197897
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
FCRL2 also known as FC Receptor-like 2 or CD307b belongs to the family of Fc receptor-like molecules. It is a transmembrane receptor with a mass of approximately 110 kDa. FCRL2 shows expression mainly in B cells with higher levels notably in some mature B cell subtypes found in the lymphoid tissues. Its expression is significantly observed in the follicles of the spleen and tonsils indicating a role in the immune responses centered around these tissues.
Biological function summary
FCRL2 modulates signaling in B cells partaking in immune regulation. It participates in the regulatory networks that adjust B-cell function and differentiation but it does not form any known complex with other proteins. The protein has a structural similarity to classical Fc receptors that suggests a modulatory role in immune response. Researchers consider FCRL2 significant in altering B cell receptor signaling though the exact ligands remain under active investigation.
Pathways
The protein FCRL2 integrates into immune signaling pathways such as the B cell receptor (BCR) signaling pathway. This pathway plays a direct role in B cell activation and antibody production. FCRL2 interacts with other FCRLS members in such pathways to maintain immune homeostasis. The extent of its integration implies a fine-tuning of B cell functions and links to Fcγ receptors indicating a shared regulatory network in pathways.
FCRL2 associates with conditions like chronic lymphocytic leukemia (CLL) and autoimmune diseases. Increased expression of FCRL2 often correlates with certain leukemia subtypes hinting at its potential as a biomarker for disease progression. Moreover its dysregulation may contribute to autoimmune conditions where B cell dysfunctions are central. Studies have also connected FCRL2 with other immune-regulatory proteins in these diseases further highlighting its relevance in pathological conditions related to immune response dysregulation.